Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways.
about
The Role of Infectious Agents in the Etiology of Ocular Adnexal NeoplasiaAngiogenesis, Kaposi's Sarcoma and Kaposi's Sarcoma-Associated HerpesvirusProgressive accumulation of activated ERK2 within highly stable ORF45-containing nuclear complexes promotes lytic gammaherpesvirus infectionDistinct roles for extracellular signal-regulated kinase 1 (ERK1) and ERK2 in the structure and production of a primate gammaherpesvirusActivation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replicationTpl2/AP-1 enhances murine gammaherpesvirus 68 lytic replication.Molecular biology of KSHV in relation to AIDS-associated oncogenesis.Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2.Robust inference of the context specific structure and temporal dynamics of gene regulatory networkLatent KSHV infection of endothelial cells induces integrin beta3 to activate angiogenic phenotypesHuman viruses and cancer.Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCγ1 and activating NFAT1-dependent RCAN1 expression.Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus Latency and ReactivationMolecular biology of KSHV lytic reactivation.Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasionMolecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesisUses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.Extracellular Hsp90 serves as a co-factor for NF-κB activation and cellular pathogenesis induced by an oncogenic herpesvirus.Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulationCelecoxib Inhibits the Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus through Down-Regulation of RTA Expression by Inhibiting the Activation of p38 MAPK.Cellular MicroRNA Let-7a Suppresses KSHV Replication through Targeting MAP4K4 Signaling Pathways.ORF45-Mediated Prolonged c-Fos Accumulation Accelerates Viral Transcription during the Late Stage of Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1Signaling cascades triggered by bacterial metabolic end products during reactivation of Kaposi's sarcoma-associated herpesvirus.Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases.An APE1 inhibitor reveals critical roles of the redox function of APE1 in KSHV replication and pathogenic phenotypesAmplification of JNK signaling is necessary to complete the murine gammaherpesvirus 68 lytic replication cycle.Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathwaysKaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency.Exploitation of Cellular Cytoskeletons and Signaling Pathways for Cell Entry by Kaposi's Sarcoma-Associated Herpesvirus and the Closely Related Rhesus Rhadinovirus.Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection.Central nervous system cytokine gene expression: modulation by lead.Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherinGenetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program.JNK and p38 mitogen-activated protein kinase pathways contribute to porcine circovirus type 2 infection.Enrichment constrained time-dependent clustering analysis for finding meaningful temporal transcription modules.The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells
P2860
Q27486618-1B21C5CA-D933-4646-B9ED-23C61DDCD2D2Q28750291-CCA5D129-1E08-4C7B-B06C-ABB9E441AF38Q30413848-2AFBD805-D688-45A9-ABAB-675DF0987157Q30422254-C7E1E882-1BEF-4859-9F6D-BCB53A38E9B9Q30441657-3E7CF530-1DB6-4836-88CD-21E341762BD4Q30919407-CE1954F6-5F7D-4401-8594-437DACD7B5BCQ33560572-71C1B43C-CF74-4B4F-A978-DE6E67A2A21CQ33667093-3162B929-EB0E-455C-99E4-46716704B2A5Q33766577-C7CEC36A-FE82-41B6-8B0E-72D70A4A9945Q34102739-5AADD3DA-505E-4E38-9068-DDB2C6EBC53CQ34423461-F80CCB06-F95C-4183-B10C-8A856610019AQ34426472-E54595BE-8FDF-42F4-88EF-4102ACF13333Q34648384-43D56AAD-5A80-40F3-8B82-4A69C7865B5DQ35010647-67E7F964-9DF3-4FCC-B1EE-B6DE9E623CBCQ35014918-8F7072AD-2C2B-4CEA-B202-D4E68613861AQ35077642-51B9ACCA-09A9-48A9-9240-5C205FAD7503Q35124404-DE51EFB7-1360-4E3F-A980-AADAB61D11BEQ35221333-4068607D-D205-49AB-A739-28A95F7A83DDQ35298119-7195F02B-36E3-4AEC-92B0-09973493DA99Q35317995-A0E9AA5F-6AB8-4E04-A170-EDC00540AD7BQ35675995-BCC46153-F816-4F10-AC17-CB92B357ADBBQ35703145-5EEA2232-D84B-4F48-8F8D-37C6D85390AFQ35745462-499C1E3D-D564-4D30-9E00-E2885B56F15BQ35785255-81BDCE73-3EFE-4A86-B394-A8DCFAA80AB8Q35857793-7DAC6CB6-CA26-4F8E-90D6-EF5DB1E76B70Q35914351-2B64A6BE-707F-4247-B387-53D2E95E936DQ36336086-0ADE4EC1-9B57-4E2B-9265-E45FD45E6BB6Q36414290-7441C586-A56A-4A42-8A07-795CB4C56DABQ36454456-A81CF505-D43D-4EEF-8A16-08A25AEBE0C9Q36506932-78A31C74-20F5-4F25-8D2E-1E33075646FEQ36540187-927B64C1-F992-4E8F-B49B-B1C79AE998F7Q36607885-B32B4B78-D4ED-422F-A997-3B94708641CBQ36673413-90E2C53F-026D-4377-B8A5-38469B3488FEQ36791915-BBA49FA8-D5A6-43A6-9DDF-6ECCDDFD3A88Q36804407-AFF62CFE-C336-4804-9490-C057D4F2D8BCQ36974720-18C3AA7E-234C-4BE9-A7EE-8F192C861C1BQ37060535-1ABFE801-13A3-497A-BE15-C86EB592E6CCQ37204640-016A22DF-82FA-46E8-BEBA-2444A1A2EA59Q37206410-3570B470-E224-409A-A683-F2CE89BB4FF8Q37288834-FD2F9B01-2DE9-45E2-B7D6-C69B242BF462
P2860
Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Kaposi's sarcoma-associated he ...... ivated protein kinase pathways
@nl
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@ast
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en-gb
type
label
Kaposi's sarcoma-associated he ...... ivated protein kinase pathways
@nl
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@ast
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en-gb
prefLabel
Kaposi's sarcoma-associated he ...... ivated protein kinase pathways
@nl
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@ast
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en-gb
P2093
P2860
P1433
P1476
Kaposi's sarcoma-associated he ...... vated protein kinase pathways.
@en
P2093
Hongyi Pan
Jianping Xie
Seungmin Yoo
P2860
P304
15027-15037
P356
10.1128/JVI.79.24.15027-15037.2005
P407
P577
2005-12-01T00:00:00Z